JP2018039833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018039833A5 JP2018039833A5 JP2017213526A JP2017213526A JP2018039833A5 JP 2018039833 A5 JP2018039833 A5 JP 2018039833A5 JP 2017213526 A JP2017213526 A JP 2017213526A JP 2017213526 A JP2017213526 A JP 2017213526A JP 2018039833 A5 JP2018039833 A5 JP 2018039833A5
- Authority
- JP
- Japan
- Prior art keywords
- dna
- seq
- identity
- clostridium
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 34
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 9
- 210000003289 regulatory T cell Anatomy 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 4
- 230000001580 bacterial Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 241000193464 Clostridium sp. Species 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 241000193403 Clostridium Species 0.000 claims 2
- 101700064140 FOXP3 Proteins 0.000 claims 2
- 241000904817 Lachnospiraceae bacterium Species 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241001505572 Anaerostipes caccae Species 0.000 claims 1
- 241000428313 Anaerotruncus colihominis Species 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 241000186560 Blautia coccoides Species 0.000 claims 1
- 241001112696 Clostridia Species 0.000 claims 1
- 241000904825 Clostridiales bacterium Species 0.000 claims 1
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 claims 1
- 241000711946 Erysipelotrichaceae bacterium Species 0.000 claims 1
- 241001531274 Faecalicatena contorta Species 0.000 claims 1
- 241001134569 Flavonifractor plautii Species 0.000 claims 1
- 241001674997 Hungatella hathewayi Species 0.000 claims 1
- 241001528479 Pseudoflavonifractor capillosus Species 0.000 claims 1
- 241000134861 Ruminococcus sp. Species 0.000 claims 1
- 241000342876 [Clostridium] asparagiforme Species 0.000 claims 1
- 241001246487 [Clostridium] bolteae Species 0.000 claims 1
- 241000985249 [Clostridium] indolis Species 0.000 claims 1
- 241001098250 [Clostridium] lavalense Species 0.000 claims 1
- 241000685809 [Clostridium] saccharogumia Species 0.000 claims 1
- 241001656794 [Clostridium] saccharolyticum Species 0.000 claims 1
- 241001147801 [Clostridium] scindens Species 0.000 claims 1
- 241000193450 [Clostridium] symbiosum Species 0.000 claims 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000001506 immunosuppresive Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 102000003995 transcription factors Human genes 0.000 claims 1
- 108090000464 transcription factors Proteins 0.000 claims 1
Claims (7)
- 制御性Ｔ細胞の増殖および／または集積を誘導する組成物であって、
有効成分として、
配列番号１９のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、クロストリジウム・サッカログミア（Clostridium saccharogumia）またはクロストリジウム・ラモーサム（Clostridium ramosum）；
配列番号２１のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、フラボニフラクター・プラウティ（Flavonifractor plautii）またはシュードフラボニフラクター・カピローサス（Pseudoflavonifractor capillosus）；
配列番号２２のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、クロストリジウム・ハセワイ（Clostridium hathewayi）またはクロストリジウム・サッカロリティカム（Clostridium saccharolyticum）；
配列番号２４のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、ブラウティア・ココイデス（Blautia coccoides）またはラクノスピラ菌（Lachnospiraceae bacterium）；
配列番号２５のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、クロストリジウム菌種（Clostridium sp.）またはクロストリジウム・ボルテアエ（Clostridium bolteae）；
配列番号２６のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、ｃｆ．クロストリジウム菌種（cf.Clostridium sp.）またはエリシペロトリクス菌（Erysipelotrichaceae bacterium）；
配列番号２７のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、クロストリジウム・インドリス（Clostridium indolis）またはアナエロスティペス・カカエ（Anaerostipes caccae）；
配列番号３０のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、アナエロツルンカス・コリホミニス（Anaerotruncus colihominis）；
配列番号３１のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、ルミノコッカス菌種（Ruminococcus sp.）またはラクノスピラ菌（Lachnospiraceae bacterium）；
配列番号３２のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、クロストリジウム・ラバレンス（Clostridium lavalense）またはクロストリジウム・アスパラギホルメ（Clostridium asparagiforme）；
配列番号３３のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、クロストリジウム・シンビオサム（Clostridium symbiosum）；
配列番号２０のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、クロストリジウム・ラモーサム；
配列番号３４のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、ユーバクテリウム・コントルタム（Eubacterium contortum）またはクロストリジウム菌種；
配列番号３９のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、クロストリジウム・シンデンス（Clostridium scindens）またはラクノスピラ菌；
配列番号４０のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、ラクノスピラ菌；
配列番号４１のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、クロストリジウム菌種またはクロストリジウム菌（Clostridiales bacterium）；および
配列番号４２のＤＮＡ配列と少なくとも９５％の同一性を有するヌクレオチド配列を含むＤＮＡを含む、ラクノスピラ菌
から選択される２種類以上の細菌株を含む組成物。 - 有効成分として３種類以上の細菌株を含む、請求項１に記載の組成物。
- 有効成分として４種類以上の細菌株を含む、請求項１に記載の組成物。
- 有効成分として５種類以上の細菌株を含む、請求項１に記載の組成物。
- （ａ）制御性Ｔ細胞が、転写因子Ｆｏｘｐ３陽性の制御性Ｔ細胞、ＩＬ−１０産生性の制御性Ｔ細胞、またはＨｅｌｉｏｓ陰性Ｆｏｘｐ３陽性の制御性Ｔ細胞であるか；および／または
（ｂ）組成物が、免疫抑制作用を有する、請求項１〜４のいずれか１項に記載の組成物。 - 請求項１〜５のいずれか１項に記載の組成物と薬学的に許容される成分とを含む医薬組成物。
- （ａ）必要とする個体において制御性Ｔ細胞の増殖、集積または増殖と集積の両方を誘導し；
（ｂ）必要とする個体において、自己免疫疾患、炎症性疾患、アレルギー疾患、および感染症から選択される少なくとも１つの疾患を治療する、その疾患の治療を補助する、その疾患の重症度を軽減する、またはその疾患を予防する
方法における使用のための、請求項１〜５のいずれか１項に記載の組成物または請求項６に記載の医薬組成物。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161565976P | 2011-12-01 | 2011-12-01 | |
| US61/565,976 | 2011-12-01 | ||
| US201261607360P | 2012-03-06 | 2012-03-06 | |
| US61/607,360 | 2012-03-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526308A Division JP6306507B2 (ja) | 2011-12-01 | 2012-11-29 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019038453A Division JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018039833A JP2018039833A (ja) | 2018-03-15 |
| JP2018039833A5 true JP2018039833A5 (ja) | 2018-05-10 |
| JP6492151B2 JP6492151B2 (ja) | 2019-03-27 |
Family
ID=48535050
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526308A Active JP6306507B2 (ja) | 2011-12-01 | 2012-11-29 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2017213526A Active JP6492151B2 (ja) | 2011-12-01 | 2017-11-06 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2019038453A Active JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2021005834A Active JP7165218B2 (ja) | 2011-12-01 | 2021-01-18 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2022168855A Active JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526308A Active JP6306507B2 (ja) | 2011-12-01 | 2012-11-29 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019038453A Active JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2021005834A Active JP7165218B2 (ja) | 2011-12-01 | 2021-01-18 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2022168855A Active JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Country Status (7)
| Country | Link |
|---|---|
| US (11) | US10238694B2 (ja) |
| EP (3) | EP3569690A1 (ja) |
| JP (5) | JP6306507B2 (ja) |
| CN (3) | CN104160014A (ja) |
| CA (1) | CA2892588A1 (ja) |
| HK (1) | HK1204008A1 (ja) |
| WO (1) | WO2013080561A1 (ja) |
Families Citing this family (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| NZ618935A (en) | 2010-08-04 | 2014-03-28 | Karma Medical Prod Co Ltd | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| RS57006B1 (sr) | 2010-10-07 | 2018-05-31 | California Inst Of Techn | Probiotičke terapije za autizam |
| JP2014507481A (ja) | 2011-03-09 | 2014-03-27 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 結腸微生物相移植のための組成物及び方法 |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| EP3569690A1 (en) | 2011-12-01 | 2019-11-20 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| WO2013130773A2 (en) | 2012-02-29 | 2013-09-06 | Ethicon Endo-Surgery, Inc. | Compositions of microbiota and methods related thereto |
| CN109172816A (zh) | 2012-03-29 | 2019-01-11 | 塞拉拜姆有限责任公司 | 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂 |
| WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| CN104768560A (zh) | 2012-08-29 | 2015-07-08 | 加州理工学院 | 孤独症谱系障碍的诊断和治疗 |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| KR102222273B1 (ko) | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
| WO2014121304A1 (en) | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
| CN105120847B (zh) | 2013-03-14 | 2018-12-28 | 塞拉拜姆有限责任公司 | 益生生物和/或治疗剂的靶向胃肠道递送 |
| US10076546B2 (en) | 2013-03-15 | 2018-09-18 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| MX367109B (es) | 2013-11-25 | 2019-08-05 | Seres Therapeutics Inc | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. |
| US9956282B2 (en) | 2013-12-16 | 2018-05-01 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| CA2944846C (en) * | 2014-04-10 | 2023-01-03 | Riken | Compositions and methods for induction of th17 cells |
| US20150322176A1 (en) * | 2014-04-16 | 2015-11-12 | University Of Guelph | Novel polysaccharide immunogens from clostridium bolteae isolated from autistic subjects and methods and uses thereof |
| EP3146065A4 (en) | 2014-05-19 | 2018-05-16 | Memorial Sloan Kettering Cancer Center | Methods and compositions for reducing clostridium difficile infection |
| CA2966363A1 (en) | 2014-10-30 | 2016-05-06 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| EP3998074A1 (en) | 2014-10-30 | 2022-05-18 | California Institute of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| EP3212001A4 (en) | 2014-10-31 | 2018-04-25 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| WO2016086161A1 (en) | 2014-11-25 | 2016-06-02 | Memorial Sloan-Kettering Cancer Center | Intestinal microbiota and gvhd |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| EA035925B1 (ru) | 2014-12-23 | 2020-09-01 | 4Д Фарма Рисерч Лимитед | Полипептид и иммуномодуляция |
| EP3065748B1 (en) | 2014-12-23 | 2017-11-22 | 4D Pharma Research Limited | A bacteroides thetaiotaomicron strain and its use in reducing inflammation |
| WO2016110768A1 (en) * | 2015-01-07 | 2016-07-14 | Ecole Polytechnique Federale De Lausanne (Epfl) | Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies |
| CN107949391B (zh) | 2015-05-14 | 2021-11-09 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
| ES2909456T3 (es) | 2015-05-22 | 2022-05-06 | Univ Arizona State | Métodos para tratar el trastorno del espectro autista y síntomas asociados |
| CA2988693A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| JP6439037B2 (ja) | 2015-06-15 | 2018-12-19 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| MD3240554T2 (ro) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| EA201890097A1 (ru) * | 2015-06-22 | 2018-07-31 | Президент Энд Феллоуз Оф Гарвард Колледж | Индукция регуляторных т-клеток lamina propria |
| EP3314007B1 (en) | 2015-06-25 | 2024-01-24 | Native Microbials, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| US10851399B2 (en) | 2015-06-25 | 2020-12-01 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| US9938558B2 (en) | 2015-06-25 | 2018-04-10 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| CA3006057A1 (en) * | 2015-09-09 | 2017-03-16 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with thyroid health issues |
| AU2016349364A1 (en) | 2015-11-03 | 2018-05-24 | The Brigham And Women's Hospital, Inc. | Therapeutic microbiota for the treatment and/or prevention of food allergy |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| RS57138B1 (sr) | 2015-11-20 | 2018-07-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| GB201520638D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| NZ743958A (en) | 2016-01-07 | 2023-07-28 | Native Microbials Inc | Methods for improving milk production by administration of microbial consortia |
| JP6675752B2 (ja) * | 2016-02-23 | 2020-04-01 | 国立大学法人佐賀大学 | 腸内Ｂｌａｕｔｉａ ｃｏｃｃｏｉｄｅｓ増殖刺激剤 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| BR112018067689A2 (pt) | 2016-03-04 | 2019-01-08 | 4D Pharma Plc | composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral |
| CN109715177A (zh) | 2016-03-14 | 2019-05-03 | 赫罗微生物群公司 | 调节消化道微生物组以治疗精神病或中枢神经***疾病 |
| WO2017160944A2 (en) | 2016-03-15 | 2017-09-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing graft versus host disease |
| EP3468391B1 (en) * | 2016-06-10 | 2020-12-09 | N.V. Nutricia | Risk of allergy and nutrition to reduce that risk |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| JP7168558B2 (ja) * | 2016-06-14 | 2022-11-09 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10722600B2 (en) | 2016-06-17 | 2020-07-28 | New York University | Methods and compositions for treating cancer |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| JP6408092B2 (ja) * | 2016-08-29 | 2018-10-17 | 国立大学法人 東京大学 | 糞便微生物叢を含む組成物 |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11447738B2 (en) | 2016-10-28 | 2022-09-20 | Vedanta Biosciences, Inc. | Methods and compositions for preserving bacteria |
| WO2018084172A1 (ja) * | 2016-11-01 | 2018-05-11 | 学校法人慶応義塾 | Ｔｈ１細胞を誘導する細菌 |
| WO2018094190A2 (en) * | 2016-11-18 | 2018-05-24 | Sanford Burnham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2018107365A1 (zh) * | 2016-12-13 | 2018-06-21 | 深圳华大基因研究院 | 粪厌氧棒杆菌(Anaerostipes caccae)及其应用 |
| CA3122548A1 (en) * | 2016-12-23 | 2018-06-28 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
| CA3048246A1 (en) | 2016-12-28 | 2018-07-05 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon |
| US12018313B2 (en) | 2016-12-28 | 2024-06-25 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles |
| WO2018148220A1 (en) * | 2017-02-07 | 2018-08-16 | California Institute Of Technology | Modulation of gut microbiota in huntington's disease and rett syndrome |
| US10596206B1 (en) | 2017-03-14 | 2020-03-24 | Cornell University | Probiotic compositions and methods of use |
| EP3606325A4 (en) | 2017-04-03 | 2021-01-20 | Gusto Global, LLC | RATIONAL DESIGN OF BIOTHERAPEUTICS BASED ON MICROBES |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
| MX2019012680A (es) | 2017-04-28 | 2019-12-11 | Ascus Biosciences Inc | Metodos para complementar dietas con alto consumo de granos y/o alto valor energetico en rumiantes, mediante la administracion de un bioensamble sintetico de microbios, o cepas purificadas de los mismos. |
| WO2018213262A1 (en) | 2017-05-19 | 2018-11-22 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for reducing listeria monocytogenes infection or colonization |
| MA48941A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| WO2018218159A1 (en) | 2017-05-26 | 2018-11-29 | Crestovo Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| LT3638271T (lt) | 2017-06-14 | 2021-01-11 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterines padermes |
| RS60910B1 (sr) | 2017-06-14 | 2020-11-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijski soj roda megasphaera i njihove upotrebe |
| GB201709763D0 (en) * | 2017-06-19 | 2017-08-02 | Probi Ab | Biological materials and methods |
| JP2020529478A (ja) * | 2017-08-04 | 2020-10-08 | セカンド ゲノム インコーポレイテッド | バイオ治療薬としてのロゼブリア・ホミニス（ｒｏｓｅｂｕｒｉａ ｈｏｍｉｎｉｓ）、ユーバクテリウム・エリゲンス（ｅｕｂａｃｔｅｒｉｕｍ ｅｌｉｇｅｎｓ）、およびこれらの組み合わせ |
| WO2019032572A1 (en) * | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES |
| CN111328284A (zh) | 2017-08-07 | 2020-06-23 | 芬奇治疗公司 | 用于维持和恢复健康的肠道屏障的组合物和方法 |
| EP3668527A1 (en) | 2017-08-14 | 2020-06-24 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| EP3476396A1 (en) * | 2017-10-31 | 2019-05-01 | Institut Gustave Roussy | Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same |
| US10507221B2 (en) | 2017-11-09 | 2019-12-17 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| CA3081978A1 (en) * | 2017-11-09 | 2019-05-16 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| WO2019143883A2 (en) * | 2018-01-18 | 2019-07-25 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
| JP2021512638A (ja) | 2018-02-09 | 2021-05-20 | 学校法人慶應義塾 | Ｃｄ８＋ｔ細胞の誘導のための組成物および方法 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| ES2963694T3 (es) | 2018-07-10 | 2024-04-01 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2) |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| DE102018213030A1 (de) * | 2018-08-03 | 2020-02-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien |
| AU2019321681A1 (en) * | 2018-08-17 | 2021-02-25 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| AU2019351017A1 (en) | 2018-09-27 | 2021-04-29 | Finch Therapeutics Holdings Llc. | Compositions and methods for treating epilepsy and related disorders |
| WO2020071463A1 (ja) * | 2018-10-04 | 2020-04-09 | 国立研究開発法人理化学研究所 | ＩＬＣ２を標的としたＩｇＡ産生誘導方法 |
| BR112021008767A2 (pt) * | 2018-11-05 | 2021-08-17 | The University Of Chicago | métodos e composições para o tratamento de doença infecciosa, autoimune e alérgica |
| WO2020234746A1 (en) | 2019-05-18 | 2020-11-26 | Janssen Biotech, Inc. | Materials and methods for microbiome modulation |
| CN114258299A (zh) * | 2019-07-17 | 2022-03-29 | 犹他大学研究基金会 | 梭菌纲聚生体组合物以及治疗肥胖症、代谢综合征和肠易激疾病的方法 |
| EP4013850A1 (en) | 2019-08-16 | 2022-06-22 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| WO2021033042A1 (en) | 2019-08-16 | 2021-02-25 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| JP2022544588A (ja) | 2019-08-16 | 2022-10-19 | ヤンセン バイオテツク，インコーポレーテツド | クロストリジウム属細菌の最適化された培養培地 |
| WO2021102313A1 (en) * | 2019-11-22 | 2021-05-27 | Assembly Biosciences, Inc. | Compositions comprising bacterial species and methods related thereto |
| EP3895710A1 (en) | 2020-04-15 | 2021-10-20 | DSM IP Assets B.V. | Food and/or feed compositions to manage immune homeostasis |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| EP4153197A4 (en) * | 2020-05-21 | 2024-05-22 | Superbrewed Food, Inc. | METHODS OF TREATMENT OR PREVENTION OF INFECTION |
| US12011467B2 (en) | 2021-05-18 | 2024-06-18 | J. Craig Venter Institute, Inc. | Bacterial formulation |
| WO2023100977A1 (ja) * | 2021-12-02 | 2023-06-08 | 地方独立行政法人神奈川県立産業技術総合研究所 | 免疫グロブリン結合タンパク質制御によるアレルギー疾患治療法および診断法の確立 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3069074D1 (en) | 1979-11-16 | 1984-10-04 | Sterosynt Ltd | 6-alpha-9-alpha-difluoro-16-beta-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US5700787A (en) | 1994-09-02 | 1997-12-23 | Brigham & Women's Hospital, Inc. | Capsular polysaccharide immunomodulator |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| ATE407700T1 (de) | 1996-03-20 | 2008-09-15 | Univ New South Wales | Veränderung der mikrobenflora im verdauungstrakt |
| US6551632B2 (en) | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| JP2001112485A (ja) | 1999-10-19 | 2001-04-24 | Yakult Honsha Co Ltd | 腸内細菌用プライマー及び該プライマーを用いた検出方法 |
| FR2808689B1 (fr) | 2000-05-11 | 2004-09-03 | Agronomique Inst Nat Rech | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| SV2003000753A (es) | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
| WO2002080963A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| PE20030283A1 (es) | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| US20040219160A1 (en) | 2003-03-31 | 2004-11-04 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
| WO2004104175A2 (en) | 2003-05-14 | 2004-12-02 | University Of Georgia Research Foundation, Inc. | Probiotic bacteria and methods |
| JP2005124495A (ja) | 2003-10-24 | 2005-05-19 | Yakult Honsha Co Ltd | ヒト腸内細菌検出用プライマー |
| JPWO2005094886A1 (ja) | 2004-03-31 | 2008-02-14 | キリンファーマ株式会社 | Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物 |
| US8092793B2 (en) | 2004-12-15 | 2012-01-10 | Qingdao East Sea Pharmaceuticals, Ltd. | Treating inflammatory bowel disease with live bacteria |
| KR101312745B1 (ko) | 2005-03-03 | 2013-09-27 | 가부시키가이샤 메이지 | 면역기능 조정제 |
| CU23581A1 (es) * | 2005-10-28 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer |
| WO2007092451A2 (en) | 2006-02-06 | 2007-08-16 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
| DE102006062250A1 (de) | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden |
| ES2399993T3 (es) | 2007-03-02 | 2013-04-04 | Protectimmun Gmbh | Composición farmacéutica para la protección frente a alergias y enfermedades inflamatorias |
| EP1974743A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
| CN101310730A (zh) | 2007-05-27 | 2008-11-26 | 青岛东海药业有限公司 | 酪酸梭菌在制备防治类风湿性关节炎、强直性脊柱炎微生物制剂中的应用 |
| JP2009084215A (ja) | 2007-09-28 | 2009-04-23 | Nippon Paper Chemicals Co Ltd | 炎症性腸疾患予防・治療剤 |
| WO2009050486A2 (en) | 2007-10-19 | 2009-04-23 | The University Of Surrey | Peptide manipulators of regulatory t cell activity |
| US20090124573A1 (en) | 2007-11-09 | 2009-05-14 | Sarkis Mazmanian | Immunomodulating compounds and related compositions and methods |
| CN101496819A (zh) | 2008-01-31 | 2009-08-05 | 青岛东海药业有限公司 | 真杆菌、梭菌制剂及其应用 |
| KR100913405B1 (ko) | 2008-03-25 | 2009-08-21 | 광주과학기술원 | Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물 |
| WO2009149149A1 (en) | 2008-06-04 | 2009-12-10 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
| JP2010129134A (ja) | 2008-11-28 | 2010-06-10 | Pulstec Industrial Co Ltd | ホログラム記録装置及びホログラム再生装置 |
| CA2752617A1 (en) | 2009-02-13 | 2010-08-19 | Samir Mitragotri | System, method and device for tissue-based diagnosis |
| GB0903016D0 (en) | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| JP2012524910A (ja) | 2009-04-23 | 2012-10-18 | カリフォルニア インスティチュート オブ テクノロジー | 免疫調節物質の同定方法及びシステム |
| US20100311686A1 (en) | 2009-06-03 | 2010-12-09 | Kasper Lloyd H | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
| WO2011005756A1 (en) | 2009-07-06 | 2011-01-13 | Puretech Ventures, Llc | Delivery of agents targeted to microbiota niches |
| WO2011022542A2 (en) | 2009-08-19 | 2011-02-24 | Puretech Ventures, Llc | Administration of factors normally present in a microbial niche to improve health |
| US20120149584A1 (en) | 2009-08-21 | 2012-06-14 | Bernat Olle | Methods of diagnosing and treating microbiome-associated disease using interaction network parameters |
| WO2011027956A2 (ko) | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 |
| US20120276149A1 (en) * | 2009-10-15 | 2012-11-01 | Dan Littman | Methods for modulating bacterial infection |
| JP5600179B2 (ja) | 2009-11-11 | 2014-10-01 | アリメンタリー、ヘルス、リミテッド | ビフィズス菌株 |
| EP2556835B1 (en) * | 2010-02-10 | 2015-08-05 | Japan Eco-Science Co. Ltd. | Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism |
| WO2011151941A1 (ja) * | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| WO2012013861A2 (en) | 2010-07-26 | 2012-02-02 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| US20120020941A1 (en) | 2010-07-26 | 2012-01-26 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| ES2388662B1 (es) | 2010-11-10 | 2014-04-11 | Consejo Superior De Investigaciones Científicas (Csic) | Nuevas cepas de duganella aisladas de la rizosfera de olivo silvestre y cultivado y su uso en la producción de violaceína. |
| US20120279149A1 (en) * | 2011-05-04 | 2012-11-08 | Sebastian George Quinn | System and device for utilization of energy in buildings |
| US20140171339A1 (en) * | 2011-06-06 | 2014-06-19 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting adenomas, colorectal cancer, and uses thereof |
| CA2848762C (en) | 2011-09-14 | 2021-07-27 | Queen's University At Kingston | Method for treatment of disorders of the gastrointestinal system |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| EP3569690A1 (en) | 2011-12-01 | 2019-11-20 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| CA2896795A1 (en) | 2012-11-26 | 2014-05-30 | Thomas Julius Borody | Compositions for the restoration of a fecal microbiota and methods for making and using them |
| KR102222273B1 (ko) | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
| CN105120847B (zh) | 2013-03-14 | 2018-12-28 | 塞拉拜姆有限责任公司 | 益生生物和/或治疗剂的靶向胃肠道递送 |
| US20160040215A1 (en) | 2013-03-14 | 2016-02-11 | Seres Therapeutics, Inc. | Methods for Pathogen Detection and Enrichment from Materials and Compositions |
| US10076546B2 (en) | 2013-03-15 | 2018-09-18 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
| WO2015006355A2 (en) | 2013-07-09 | 2015-01-15 | Puretech Ventures, Llc | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| CA2944846C (en) | 2014-04-10 | 2023-01-03 | Riken | Compositions and methods for induction of th17 cells |
| WO2015198105A1 (en) | 2014-06-27 | 2015-12-30 | Telefonaktiebolaget L M Ericsson (Publ) | System and method for supporting time-sensitive services in a communication network |
| AU2015284782B2 (en) | 2014-06-30 | 2020-05-07 | Salix Pharmaceuticals, Inc. | Methods for retreating Irritable Bowel Syndrome (IBS) |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| AU2016272114B2 (en) | 2015-05-30 | 2019-09-12 | Japan Eco-Science Co., Ltd. | Probiotic or prebiotic, method for producing same, microbial preparation, health food, and medicine |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US9642281B1 (en) * | 2015-12-28 | 2017-05-02 | Martas Precision Slide Co., Ltd. | Buckle set for sliding rail of industrial rackmount chassis |
| CN109715177A (zh) * | 2016-03-14 | 2019-05-03 | 赫罗微生物群公司 | 调节消化道微生物组以治疗精神病或中枢神经***疾病 |
| US20170290889A1 (en) | 2016-04-11 | 2017-10-12 | New York University | Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders |
| JP6792103B2 (ja) | 2016-06-01 | 2020-11-25 | 株式会社テックコーポレーション | 微細気泡水供給システム |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| WO2018084172A1 (ja) | 2016-11-01 | 2018-05-11 | 学校法人慶応義塾 | Ｔｈ１細胞を誘導する細菌 |
| CA3122548A1 (en) * | 2016-12-23 | 2018-06-28 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
| WO2019032572A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES |
| JP2019046634A (ja) * | 2017-08-31 | 2019-03-22 | パナソニックＩｐマネジメント株式会社 | 照明システム及びコントローラ |
| US10507221B2 (en) * | 2017-11-09 | 2019-12-17 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
-
2012
- 2012-11-29 EP EP19178787.8A patent/EP3569690A1/en active Pending
- 2012-11-29 CN CN201280068081.8A patent/CN104160014A/zh active Pending
- 2012-11-29 EP EP21198256.6A patent/EP3978598A1/en active Pending
- 2012-11-29 CA CA2892588A patent/CA2892588A1/en active Pending
- 2012-11-29 EP EP12854485.5A patent/EP2785828B1/en active Active
- 2012-11-29 CN CN202310526067.8A patent/CN116942833A/zh active Pending
- 2012-11-29 US US14/362,097 patent/US10238694B2/en active Active
- 2012-11-29 CN CN201810228890.XA patent/CN108676774B/zh active Active
- 2012-11-29 WO PCT/JP2012/007687 patent/WO2013080561A1/en active Application Filing
- 2012-11-29 JP JP2014526308A patent/JP6306507B2/ja active Active
-
2015
- 2015-05-15 HK HK15104633.8A patent/HK1204008A1/xx unknown
-
2016
- 2016-02-09 US US15/019,068 patent/US9642881B2/en active Active
- 2016-02-09 US US15/019,101 patent/US9649345B2/en active Active
-
2017
- 2017-03-28 US US15/471,493 patent/US10052353B2/en active Active
- 2017-04-14 US US15/487,553 patent/US10058578B2/en active Active
- 2017-11-06 JP JP2017213526A patent/JP6492151B2/ja active Active
-
2018
- 2018-04-27 US US15/964,285 patent/US10183045B2/en active Active
- 2018-10-15 US US16/160,004 patent/US10342832B2/en active Active
- 2018-10-25 US US16/170,344 patent/US10835559B2/en active Active
-
2019
- 2019-03-04 JP JP2019038453A patent/JP7097838B2/ja active Active
- 2019-05-31 US US16/427,899 patent/US10624933B2/en active Active
-
2020
- 2020-10-15 US US17/071,425 patent/US11547732B2/en active Active
-
2021
- 2021-01-18 JP JP2021005834A patent/JP7165218B2/ja active Active
-
2022
- 2022-10-21 JP JP2022168855A patent/JP7503273B2/ja active Active
- 2022-12-20 US US18/068,725 patent/US20240000858A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018039833A5 (ja) | ||
| JP2021078504A5 (ja) | ||
| WO2017044507A3 (en) | Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection | |
| FI3380108T3 (fi) | Suunniteltuja bakteerikoostumuksia | |
| WO2017049227A3 (en) | Wedge dissectors for a medical ballon | |
| JP2015500792A5 (ja) | ||
| WO2016100807A3 (en) | Human antibodies to influenza hemagglutinin | |
| WO2010036945A3 (en) | Nanoemulsion therapeutic compositions and methods of using the same | |
| EP4353254A3 (en) | Methods for treating skin infection by administering an il-4r antagonist | |
| JP2019500056A5 (ja) | ||
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| WO2016142708A3 (en) | Pharmaceutical composition | |
| WO2015148768A3 (en) | Onconase for use in treating or preventing viral infections | |
| PH12020500569A1 (en) | Influenza virus vaccines and uses thereof | |
| WO2016086153A3 (en) | Use of hsp90 inhibitors for the treatment of hiv infections and aids | |
| WO2018004224A3 (ko) | 신규 스포리치아과 미생물 및 그의 용도 | |
| WO2021004958A3 (en) | Compositions comprising bacterial strains | |
| WO2016100615A3 (en) | Methods and composition for neutralization of influenza | |
| WO2017123610A3 (en) | Bacteria engineered to detoxify deleterious molecules | |
| SG10201907542SA (en) | Active substances of bifidobacterium lactis gkk2, composition comprising the same and method of promoting longevity using the same | |
| MX2017007969A (es) | Bacterias de acido lactico y su uso para el tratamiento de mastitis. | |
| MX2022002766A (es) | Vacunas contra el virus de la gripe y usos de las mismas. | |
| WO2015086738A3 (en) | Hiv vaccine | |
| WO2017158616A8 (en) | Carbapenem compounds | |
| WO2019079618A3 (en) | Formulations for treatment of skin conditions |